PATENT CLAIM ANALYSIS

Application Number: 15918582
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["424", "464000"]

Abstract:
The present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The solid pharmaceutical dosage forms may rapidly disintegrates in a patient's oral cavity.

Claim (Index 28):
A solid oral dosage form comprising 0.1 mg to 1 mg of fingolimod lauryl sulfate salt and at least one pharmaceutically acceptable excipient, wherein following a single dose administration of the solid oral dosage form to healthy human adults under fasting conditions, the time to maximum fingolimod concentration (T max ) is about 10 to about 35 hours, the dose adjusted maximum fingolimod concentration (C max/dose ) is about 0.55 to about 1.5 ng/ml/mg, and the dose adjusted area under the plasma concentration-time curve (AUC 0-\u221e/dose ) is about 125 to about 275 ng\u00b7hr/ml/mg.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 90.0
- Lexical Diversity: 1.2973
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15084226', '13564362', '14087903', '13183119', '13719640']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7117457778835574
- 35 USC 102 Novelty (BERT): 0.5460815769568678
- Combined Prediction Score: 0.6951793577908885
- Mean Citation Score: 241.714678
- Max Citation Score: 402.46573
- Similarity Product: 338.09262466731184

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test